BioCryst Appoints Steve Frank to Board of Directors
BioCryst Pharmaceuticals (BCRX) has appointed Steve Frank, chairman of global healthcare investment banking at J.P. Morgan, to its board of directors. Frank brings extensive healthcare investment banking experience, having previously served as global group head of worldwide healthcare investment banking at Bear Stearns. He has a notable background in institutional investing, having built State Farm's multi-billion-dollar life science equity portfolio in the 1980s and early 1990s.
The company highlighted its strong position with a commercial product approaching $1 billion in peak sales, a robust cash position independent of capital markets, and a pipeline of potential best-in-class medicines in development. Frank currently serves on Precigen's board and holds a CFA designation, along with degrees from Illinois State University and the University of Chicago.
BioCryst Pharmaceuticals (BCRX) ha nominato Steve Frank, presidente del settore bancario globale per investimenti in ambito sanitario presso J.P. Morgan, nel suo consiglio di amministrazione. Frank porta con sé una vasta esperienza nel settore bancario per investimenti sanitari, avendo ricoperto in precedenza il ruolo di responsabile globale del gruppo di investment banking sanitario presso Bear Stearns. Vanta inoltre un solido background negli investimenti istituzionali, avendo creato il portafoglio azionario nel settore delle scienze della vita da miliardi di dollari di State Farm negli anni '80 e all'inizio degli anni '90.
L'azienda ha sottolineato la sua posizione solida con un prodotto commerciale che si avvicina a $1 miliardo di vendite di picco, una robusta liquidità indipendente dai mercati finanziari e una pipeline di potenziali farmaci di prima classe in fase di sviluppo. Frank attualmente fa parte del consiglio di Precigen, possiede la certificazione CFA e ha conseguito lauree presso la Illinois State University e l'Università di Chicago.
BioCryst Pharmaceuticals (BCRX) ha nombrado a Steve Frank, presidente de banca de inversión global en el sector sanitario en J.P. Morgan, como miembro de su junta directiva. Frank aporta una amplia experiencia en banca de inversión sanitaria, habiendo sido anteriormente jefe global del grupo de banca de inversión sanitaria mundial en Bear Stearns. Cuenta con una destacada trayectoria en inversión institucional, habiendo construido la cartera de acciones en ciencias de la vida de varios miles de millones de dólares para State Farm en los años 80 y principios de los 90.
La compañía destacó su sólida posición con un producto comercial que se acerca a $1 mil millones en ventas máximas, una fuerte posición de efectivo independiente de los mercados de capital y una cartera de medicamentos potencialmente líderes en desarrollo. Frank actualmente forma parte de la junta de Precigen, posee la certificación CFA y tiene títulos de la Illinois State University y la University of Chicago.
BioCryst Pharmaceuticals (BCRX)는 J.P. Morgan의 글로벌 헬스케어 투자은행 부문 의장인 Steve Frank를 이사회에 임명했습니다. Frank는 Bear Stearns에서 전 세계 헬스케어 투자은행 그룹장을 역임하는 등 폭넓은 헬스케어 투자은행 경험을 보유하고 있습니다. 또한 1980년대와 1990년대 초에 State Farm의 수십억 달러 규모 생명과학 주식 포트폴리오를 구축한 기관 투자 분야에서의 뛰어난 경력을 가지고 있습니다.
회사는 최고 매출 10억 달러에 가까운 상업용 제품, 자본 시장과 무관한 탄탄한 현금 보유고, 그리고 개발 중인 잠재적 최고 수준의 의약품 파이프라인을 강조했습니다. Frank는 현재 Precigen 이사회에 재직 중이며 CFA 자격증과 Illinois State University 및 University of Chicago 학위를 보유하고 있습니다.
BioCryst Pharmaceuticals (BCRX) a nommé Steve Frank, président de la banque d'investissement mondiale en santé chez J.P. Morgan, à son conseil d'administration. Frank apporte une vaste expérience en banque d'investissement dans le secteur de la santé, ayant précédemment été responsable mondial du groupe de banque d'investissement santé chez Bear Stearns. Il possède un solide parcours en investissement institutionnel, ayant constitué le portefeuille d'actions en sciences de la vie de plusieurs milliards de dollars de State Farm dans les années 1980 et au début des années 1990.
L'entreprise a mis en avant sa position solide avec un produit commercial approchant 1 milliard de dollars de ventes maximales, une trésorerie robuste indépendante des marchés financiers, et un pipeline de médicaments potentiellement de premier plan en développement. Frank siège actuellement au conseil de Precigen, détient la certification CFA et est diplômé de l'Illinois State University et de l'Université de Chicago.
BioCryst Pharmaceuticals (BCRX) hat Steve Frank, Vorsitzender des globalen Gesundheitsinvestmentbankings bei J.P. Morgan, in seinen Vorstand berufen. Frank bringt umfassende Erfahrung im Gesundheitsinvestmentbanking mit, nachdem er zuvor als globaler Gruppenleiter für weltweites Gesundheitsinvestmentbanking bei Bear Stearns tätig war. Er verfügt über eine bemerkenswerte Erfahrung im institutionellen Investieren, nachdem er in den 1980er und frühen 1990er Jahren das milliardenschwere Life-Science-Aktienportfolio von State Farm aufgebaut hat.
Das Unternehmen hob seine starke Position hervor, mit einem kommerziellen Produkt, das nahezu 1 Milliarde US-Dollar Spitzenumsatz erreicht, einer robusten Liquiditätslage unabhängig von den Kapitalmärkten und einer Pipeline potenzieller erstklassiger Medikamente in der Entwicklung. Frank ist derzeit im Vorstand von Precigen tätig, besitzt die CFA-Qualifikation und hat Abschlüsse von der Illinois State University und der University of Chicago.
- Addition of experienced healthcare investment banking leader to the board
- Commercial product approaching $1 billion in peak sales potential
- Strong cash position indicating financial independence from capital markets
- Pipeline of potential best-in-class medicines in clinical development
- None.
RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors.
Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously global group head of worldwide healthcare investment banking at Bear Stearns before it was acquired by J.P. Morgan in 2008. Mr. Frank is a trusted corporate advisor, supporting countless transactions including pharmaceutical, biotechnology, medical device and healthcare services firms. A standout institutional investor before becoming a banker, Mr. Frank directed and built State Farm’s multi-billion-dollar life science equity portfolio in the 1980s and early 1990s. He maintains the accreditation as a Chartered Financial Analyst today.
“Steve is one of the most accomplished and respected healthcare investment bankers in the industry and we look forward to adding his expertise to the board. His experience with innovative business development transactions and value-creating capital allocation are a perfect fit as BioCryst builds on its commercial success, accelerates towards profitability and advances its pipeline,” said Dr. Nancy Hutson, chair of the BioCryst board of directors.
“BioCryst is uniquely positioned in the biopharma space with the rare combination of a commercial product growing closer to
Mr. Frank currently serves on the board of Precigen. He holds a B.S. from Illinois State University and an M.B.A. from the University of Chicago.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully implement or maintain its commercialization plans for ORLADEYO; BioCryst’s ability to successfully progress its pipeline development plans; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; risks related to government actions, including that decisions and other actions, including as they relate to pricing, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst’s current expectations; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance and demand; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its products and product candidates; BioCryst’s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; timing for achieving and sustainability of profitability and positive cash flow may not meet management’s expectations; statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and BioCryst’s ability to execute its operational and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management’s expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
Who is Steve Frank and why did BCRX appoint him to their board?
What is BioCryst's (BCRX) current financial position in 2025?
What is Steve Frank's background and experience?
What are BioCryst's (BCRX) current business strengths?
